ReviewBiosensors2021
Liquid Biopsy-Based Biosensors for MRD Detection and Treatment Monitoring in Non-Small Cell Lung Cancer (NSCLC).
Review in Biosensors, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07596433 (An Observational Study on the Prediction of Recurrence Risk in Early-stage Non-small Cell Lung Cancer Using a Customized MRD Monitoring Scheme Based on Tumor Tissue WES), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Observational Study on the Prediction of Recurrence Risk in Early-stage Non-small Cell Lung Cancer Using a Customized MRD Monitoring Scheme Based on Tumor Tissue WES
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- The progress of biomarkers detection to lung cancer.Discover oncology · 2026Review
- Minimal Residual Disease Detection: Bridging Molecular and Clinical Strategies for Recurrence Prevention in Gynecologic Cancers.International journal of molecular sciences · 2025Review
- HNRNPC promotes progression of non-small cell lung cancer by maintaining TFAP2A mRNA stability.Cancer cell international · 2025Article
- Breaking barriers in cancer diagnosis: unveiling the 4Ms of biosensors.RSC advances · 2025Review
- Investigating T Cell Immune Dynamics and IL-6's Duality in a Microfluidic Lung Tumor Model.ACS applied materials & interfaces · 2025Article
- Liquid Biopsy for Medical Imaging Analysis in Cancer Diagnosis.Current pharmaceutical design · 2025Review
- Liquid Biopsy in the Clinical Management of Cancers.International journal of molecular sciences · 2024Review
- Evaluating personalized circulating tumor DNA detection for early-stage lung cancer.Cancer medicine · 2024Article
- Liquid biopsy in T-cell lymphoma: biomarker detection techniques and clinical application.Molecular cancer · 2024Review
- Global trends and research hotspots in perioperative management of lung cancer: a bibliometric analysis from 2004 to 2024.Frontiers in immunology · 2024Article
- A Narrative Review of Molecular, Immunohistochemical and In-Situ Techniques in Dermatopathology.British journal of biomedical science · 2024Review
- Circulating tumor DNA (ctDNA)-based minimal residual disease in non-small cell lung cancer.Chinese medical journal pulmonary and critical care medicine · 2023Review
- Functionalized GD2 Electrochemical Immunosensor to Diagnose Minimum Residual Disease of Bone Marrow in Neuroblastoma Effectively.Biosensors · 2023Article
- Article
- Investigate the application of postoperative ctDNA-based molecular residual disease detection in monitoring tumor recurrence in patients with non-small cell lung cancer--A retrospective study of ctDNA.Frontiers in oncology · 2023Article
- Article
- Application of Non-Blood-Derived Fluid Biopsy in Monitoring Minimal Residual Diseases of Lung Cancer.Frontiers in surgery · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Globally, non-small cell lung cancer (NSCLC) is the leading cause of cancer deaths. Despite advancements in chemotherapy and targeted therapies, the 5-year survival rate has remained at 16% for the past forty years. Minimal residual disease (MRD) is described as the existence of either isolated tumour cells or circulating tumour cells in biological liquid of patients after removal of the primary tumour without any clinical signs of cancer. Recently, liquid biopsy has been promising as a non-invasive method of disease monitoring and treatment guidelines as an MRD marker. Liquid biopsy could be used to detect and assess earlier stages of NSCLC, post-treatment MRD, resistance to targeted therapies, immune checkpoint inhibitors (ICIs) and tumour mutational burden. MRD surveillance has been proposed as a potential marker for lung cancer relapse. Principally, biosensors provide the quantitative analysis of various materials by converting biological functions into quantifiable signals. Biosensors are usually operated to detect antibodies, enzymes, DNA, RNA, extracellular vesicles (EVs) and whole cells. Here, we present a category of biosensors based on the signal transduction method for identifying biosensor-based biomarkers in liquid biopsy specimens to monitor lung cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.